| NCT06156761 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences|CSPC Ouyi Pharmaceutical Co., Ltd. | Breast Cancer | 2023-11-28 | NA |
| NCT02043756 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Neoplasms | 2011-08 | PHASE1 |
| NCT01681537 | Massachusetts General Hospital | Acute Myelogenous Leukemia | 2012-09 | PHASE1 |
| NCT00058084 | National Cancer Institute (NCI) | Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage IV Prostate Cancer | 2003-03 | PHASE2 |
| NCT05100329 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Pancreatic Cancer | 2021-11 | PHASE2 |
| NCT06224842 | Huijing Wu|Beijing Xisike Clinical Oncology Research Foundation|CSPC-NBP Pharmaceutical Co., Ltd. | Angioimmunoblastic T-cell Lymphoma | 2023-12-12 | PHASE1|PHASE2 |
| NCT02131688 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Malignant Lymphoma | 2013-05 | PHASE1 |
| NCT01523860 | Fondazione Italiana Linfomi - ETS|Centro di Riferimento per l´Epidemiologia e la Prev. Oncologica Piemonte | Follicular Lymphoma | 2009-06 | PHASE2 |
| NCT00002674 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) | Leukemia | 1994-10 | PHASE2 |
| NCT00774046 | University of Chicago | Myelodysplastic Syndrome|Acute Myeloid Leukemia | 2002-12 | PHASE2 |
| NCT00002766 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) | Leukemia|Lymphoma | 1996-03 | PHASE3 |
| NCT02101853 | National Cancer Institute (NCI) | Recurrent B Acute Lymphoblastic Leukemia | 2014-12-17 | PHASE3 |
| NCT02724163 | University of Birmingham|Assistance Publique - H?pitaux de Paris|Cancer Research UK|National Cancer Institute, France|Pfizer | Acute Myeloid Leukaemia | 2016-04 | PHASE3 |
| NCT03250338 | Arog Pharmaceuticals, Inc. | Relapsed+Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | 2018-08-16 | PHASE3 |
| NCT00770848 | Amgen | Cancer|Castrate-Resistant Prostate Cancer|Mestastatic Prostate Cancer|Prostate Cancer | 2008-11 | PHASE1|PHASE2 |
| NCT00002474 | Loyola University | Ovarian Cancer | 1991-02 | PHASE2 |
| NCT00006114 | GERCOR - Multidisciplinary Oncology Cooperative Group | Prostate Cancer | 1999-05 | PHASE2 |
| NCT06621199 | First Affiliated Hospital of Zhejiang University|CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Acute Myeloid Leukemia | 2024-07-08 | PHASE2 |
| NCT00015951 | University of Maryland, Baltimore|National Cancer Institute (NCI)|University of Maryland Greenebaum Cancer Center | Leukemia|Myelodysplastic Syndromes | 2001-04 | PHASE2 |
| NCT06345365 | Zhongnan Hospital|Ruijin Hospital|Shanxi Province Cancer Hospital|The First Affiliated Hospital of Zhengzhou University|Jingzhou Central Hospital|Yichang Central People´s Hospital|Taihe Hospital|Central Hospital of Xiaogan|Xianning Central Hospital|The First People´s Hospital of Jingzhou | Acute Myeloid Leukaemia | 2024-01-18 | PHASE3 |
| NCT00003650 | UNICANCER | Lymphoma | 1997-02 | PHASE3 |
| NCT02200978 | South China Children´s Leukemia Group | Childhood Acute Promyelocytic Leukemia | 2011-09 | PHASE4 |
| NCT06429449 | University of Colorado, Denver|The Leukemia and Lymphoma Society | Leukemia|Myeloid Leukemia|Monocytic Leukemia | 2024-07-21 | PHASE1 |
| NCT00470197 | National Cancer Institute (NCI) | Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Malignant Neoplasm|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia | 2007-04 | PHASE1 |
| NCT06472713 | Ming-Yuan Chen | Recurrent or Metastatic Nasopharyngeal Carcinoma | 2024-07-20 | PHASE2 |
| NCT06741722 | Beijing 302 Hospital | AML|Relapsed Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia | 2024-10-31 | PHASE2 |
| NCT00003405 | Rush University Medical Center|National Cancer Institute (NCI) | Leukemia | 1998-04 | PHASE2 |
| NCT00183989 | University of Southern California | Mantle Cell Lymphoma | 2000-08 | PHASE2 |
| NCT01249430 | National Cancer Institute (NCI) | Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia | 2011-01-20 | PHASE1 |
| NCT00003893 | University Hospital Birmingham | Breast Cancer | 1998-07 | PHASE3 |
| NCT07288814 | Sun Yat-Sen University Cancer Center|CSPC Ouyi Pharmaceutical Co., Ltd. | Relapsed or Refractory Peripheral T Cell Lymphoma | 2025-12-08 | PHASE1|PHASE2 |
| NCT06660368 | H. Lee Moffitt Cancer Center and Research Institute|AbbVie | Relapsed or Refractory Acute Myeloid Leukemia (AML) | 2024-11-26 | PHASE2 |
| NCT00003858 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Prostate Cancer | | PHASE2 |
| NCT01904643 | Stanford University|National Cancer Institute (NCI) | Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia | 2014-02 | PHASE1 |
| NCT00627354 | Groupe D´Etude des Tumeurs Uro-Genitales | Prostate Cancer | 2006-09 | PHASE2 |
| NCT00407966 | National Cancer Institute (NCI) | Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia | 2006-10 | PHASE2 |
| NCT00047021 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) | Leukemia|Lymphoma | 2001-11 | PHASE2 |
| NCT05772728 | The First Affiliated Hospital with Nanjing Medical University | T Cell Lymphoma | 2023-04 | NA |
| NCT03504410 | Cornerstone Pharmaceuticals | Relapsed+Refractory Acute Myeloid Leukemia | 2018-11-12 | PHASE3 |
| NCT05100303 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Treatment-naive or Relapsed or Refractory Acute Myeloid Leukemia (AML) | 2021-12 | PHASE1|PHASE2 |
| NCT00005823 | Leukemia Research Fund | Leukemia|Myelodysplastic Syndromes|Myelodysplastic+Myeloproliferative Neoplasms | 1998-12 | PHASE3 |
| NCT00002003 | Lederle Laboratories | Lymphoma, Non-Hodgkin|HIV Infections | | PHASE2 |
| NCT00609739 | Masonic Cancer Center, University of Minnesota | Leukemia | 1999-06 | PHASE1|PHASE2 |
| NCT06434662 | First Affiliated Hospital of Zhejiang University|CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Relapsed+Refractory Acute Myeloid Leukaemia|Myeloid Malignancy | 2024-02-29 | PHASE2 |
| NCT00004237 | Royal Marsden NHS Foundation Trust | Breast Cancer | 1998-10 | PHASE2 |
| NCT00199069 | Goethe University|Deutsche Krebshilfe e.V., Bonn (Germany) | Adult Acute Lymphocytic Leukemia | 1993-04 | PHASE4 |
| NCT00003602 | Riverside Haematology Group | Leukemia|Myelodysplastic Syndromes | 1998-03 | PHASE3 |
| NCT04778410 | Gilead Sciences | Myeloid Malignancies | 2021-06-28 | PHASE2 |
| NCT00107354 | Fred Hutchinson Cancer Center | Leukemia|Myelodysplastic Syndromes | 1998-12 | PHASE1 |
| NCT00268242 | The Cleveland Clinic|National Cancer Institute (NCI)|Duke University | Leukemia | 2006-01 | PHASE2 |
| NCT00203073 | Teva Branded Pharmaceutical Products R&D, Inc. | Relapsing Remitting Multiple Sclerosis | 2003-06 | PHASE2 |
| NCT00660036 | University of Pittsburgh | Acute Myeloid Leukemia | 2008-09 | PHASE1 |
| NCT05784987 | The First Affiliated Hospital with Nanjing Medical University | Diffuse Large B-cell Lymphoma | 2023-04-15 | NA |
| NCT01828489 | Vastra Gotaland Region | Pediatric Acute Myeloblastic Leukemia | 2013-03 | PHASE3 |
| NCT05464433 | Sun Yat-sen University | Extranodal Natural Killer T Cell Lymphoma | 2022-06-23 | PHASE1|PHASE2 |
| NCT00477087 | Stanford University|Bayer | Prostatic Neoplasms | 2006-07 | PHASE2 |
| NCT02583893 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia | 2015-10-07 | PHASE2 |
| NCT00003633 | Herbert Irving Comprehensive Cancer Center | Prostate Cancer | 1998-08 | PHASE1 |
| NCT06499025 | BGI, China|Shenzhen University General Hospital | AML|t(8;21)|Neoantigen | 2024-02-01 | EARLY_PHASE1 |
| NCT04668690 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Peripheral T Cell Lymphoma | 2021-04-13 | PHASE3 |
| NCT05857982 | Second Affiliated Hospital of Soochow University|The Affiliated Hospital of Xuzhou Medical University | Relapsed+Refractory Multiple Myeloma | 2023-05-20 | PHASE1|PHASE2 |
| NCT04718376 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Platinum-resistant Ovarian Cancer | 2021-01-12 | PHASE1 |
| NCT00003080 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) | Ovarian Cancer | 1996-09 | PHASE1 |
| NCT00070174 | Children´s Oncology Group|National Cancer Institute (NCI) | Leukemia | 2003-12 | PHASE2 |
| NCT00005847 | Eastern Cooperative Oncology Group|National Cancer Institute (NCI) | Prostate Cancer | 2001-04-05 | PHASE2 |
| NCT00002905 | Centro di Riferimento Oncologico - Aviano | Lymphoma | 1995-06 | PHASE2 |
| NCT02461537 | DKMS gemeinnützige GmbH | Acute Myeloid Leukemia | 2015-09-17 | PHASE3 |
| NCT00634244 | National Cancer Institute (NCI) | Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia | 2008-10 | PHASE2 |
| NCT01700946 | St. Jude Children´s Research Hospital|Cookies for Kids´ Cancer|Assisi Foundation | Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood B-Lymphoblastic Lymphoma | 2013-04-15 | PHASE2 |
| NCT00385827 | Centocor, Inc. | Cancer, Prostate | 2006-11 | PHASE2 |
| NCT00002805 | Children´s Oncology Group|National Cancer Institute (NCI) | Leukemia | 1997-08 | PHASE2 |
| NCT06892431 | Shanghai JMT-Bio Inc. | Recurrent or Metastatic Nasopharyngeal Cancer|Patients Who Have Experienced Treatment Failure at Least Second-line Chemotherapy | 2025-04-01 | PHASE2 |
| NCT02631252 | Alison Sehgal, MD, MS | Leukemia, Acute Myelogenous | 2016-08-18 | PHASE1 |
| NCT00410423 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University|Millennium Pharmaceuticals, Inc. | Relapsed Acute Leukemia|Refractory Acute Leukemia | 2006-01 | PHASE1|PHASE2 |
| NCT07525466 | Beijing Tongren Hospital | Extranodal NK T Cell Lymphoma|Hemophagocytic Lymphohistiocytosis (HLH) | 2026-04-01 | PHASE1|PHASE2 |
| NCT02596373 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Recurrent or Metastatic Breast Cancer | 2015-06 | PHASE2 |
| NCT00024492 | INSYS Therapeutics Inc | Tumors | 2001-08 | PHASE1 |
| NCT05527275 | Sun Yat-sen University | Relapsed and Refractory Peripheral T-cell Lymphoma | 2022-10-01 | PHASE1|PHASE2 |
| NCT01594918 | Rahul Aggarwal|Sanofi | Metastatic Castration-resistant Prostate Cancer | 2012-06 | PHASE1 |
| NCT00278213 | German CLL Study Group | Prolymphocytic Leukemia | 2002-09 | PHASE2 |
| NCT07093710 | Sun Yat-sen University | Peripheral T Cell Lymphoma | 2025-08-27 | PHASE1|PHASE2 |
| NCT06221683 | Children´s Hospital of Soochow University | AML, Childhood|Acute Myeloid Leukemia | 2024-01-01 | PHASE2 |
| NCT05777369 | The First Affiliated Hospital with Nanjing Medical University | Diffuse Large B-cell Lymphoma | 2023-03 | NA |
| NCT00005802 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) | Leukemia | 1999-06 | PHASE1|PHASE2 |
| NCT04718402 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Gastric Carcinoma | 2021-03-30 | PHASE1 |
| NCT00744081 | Goethe University | AML | 2004-07 | PHASE2 |
| NCT07070479 | Ming-Yuan Chen | Recurrent or Metastatic Nasopharyngeal Carcinoma | 2025-06-24 | PHASE2 |
| NCT02937285 | Rennes University Hospital | Multiple Sclerosis | 2010-12-06 | PHASE3 |
| NCT00219908 | Rennes University Hospital|Bayer|Wyeth is now a wholly owned subsidiary of Pfizer|Farmades, Italy | Relapsing-Remitting Multiple Sclerosis | 1999-07 | PHASE2 |
| NCT02518750 | St. Jude Children´s Research Hospital|Novartis Pharmaceuticals|Spectrum Pharmaceuticals, Inc | Acute Lymphoblastic Leukemia|Lymphoma, Non-Hodgkin´s|Leukemia, T-Cell|Leukemia, B-Cell | 2016-11-23 | PHASE2 |
| NCT05522192 | Hui Zeng|CSPC Ouyi Pharmaceutical Co., Ltd. | Relapsed or Refractory Acute Myeloid Leukemia | 2022-07-21 | PHASE1|PHASE2 |
| NCT02553460 | St. Jude Children´s Research Hospital|Gateway for Cancer Research|Baylor College of Medicine | Acute Lymphoblastic Leukemia | 2016-01-29 | PHASE1|PHASE2 |
| NCT00028899 | Children´s Oncology Group|National Cancer Institute (NCI) | Leukemia|Myelodysplastic Syndromes | 2002-07 | PHASE1 |
| NCT00003032 | NCIC Clinical Trials Group | Breast Cancer | 1997-04-25 | PHASE3 |
| NCT00005987 | Masonic Cancer Center, University of Minnesota | Multiple Myeloma and Plasma Cell Neoplasm | 2000-08 | PHASE2 |
| NCT00003436 | Medical Research Council | Leukemia|Myelodysplastic Syndromes | 1998-07 | PHASE3 |
| NCT00562965 | Pfizer|UCB Pharma | Lymphoma, Follicular | 2007-11 | PHASE3 |
| NCT00002576 | Cancer Research Campaign Clinical Trials Centre | Lymphoma | 1992-11 | PHASE3 |
| NCT00016016 | National Cancer Institute (NCI) | Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Adult Acute Myeloid Leukemia | 2001-02 | PHASE1|PHASE2 |
| NCT00526305 | PETHEMA Foundation | Acute Lymphoblastic Leukemia | 2000-01 | PHASE4 |
| NCT00003183 | Hope Cancer Institute, Inc. | Prostate Cancer | 1997-03 | PHASE1|PHASE2 |
| NCT03118466 | Massachusetts General Hospital|Celgene | AML | 2017-09-25 | PHASE2 |
| NCT02520011 | Sumitomo Pharma America, Inc. | Acute Myeloid Leukemia | 2016-03-14 | PHASE2 |
| NCT00002819 | Gynecologic Oncology Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group|SWOG Cancer Research Network|Cancer and Leukemia Group B | Ovarian Cancer | 1996-11 | PHASE3 |
| NCT00004001 | SWOG Cancer Research Network|National Cancer Institute (NCI)|Cancer and Leukemia Group B|North Central Cancer Treatment Group | Prostate Cancer | 1999-10 | PHASE3 |
| NCT00683475 | Eli Lilly and Company | Prostate Cancer | 2008-08 | PHASE2 |
| NCT04509466 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Extranodal NK+T-cell Lymphoma, Nasal Type | 2020-09-15 | PHASE1|PHASE2 |
| NCT01483690 | Therapeutic Advances in Childhood Leukemia Consortium | Acute Lymphoblastic Leukemia|Precursor B-Cell Lymphoblastic Leukemia|Precursor T-Cell Lymphoblastic Leukemia | 2011-12 | PHASE1|PHASE2 |
| NCT00416910 | German CLL Study Group | Chronic Lymphocytic Leukemia | 1999-07 | PHASE3 |
| NCT06447090 | Institute of Hematology & Blood Diseases Hospital, China | Relapse Acute Myeloid Leukemia | 2024-04-12 | PHASE2 |
| NCT01260714 | National Cancer Institute (NCI) | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Megakaryoblastic Leukemia|Adult Acute Monoblastic Leukemia|Adult Acute Monocytic Leukemia|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With Maturation|Adult Acute Myeloid Leukemia With Minimal Differentiation|Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1|Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL|Adult Acute Myeloid Leukemia Without Maturation|Adult Acute Myelomonocytic Leukemia|Adult Erythroleukemia|Adult Pure Erythroid Leukemia|Alkylating Agent-Related Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia | 2010-12 | PHASE1 |
| NCT01627938 | PD Dr. Andrew Chan | Multiple Sclerosis | 2012-04 | PHASE2 |
| NCT02733380 | Henan Cancer Hospital | Diffuse Large B-cell Lymphoma | 2016-05 | PHASE2 |
| NCT01578343 | Samsung Medical Center|Seok Jin Kim | Mantle Cell Lymphoma | 2012-06 | PHASE2 |
| NCT03441048 | Medical College of Wisconsin | Acute Myeloid Leukemia | 2018-05-22 | PHASE1 |
| NCT06007911 | Medical College of Wisconsin | Relapsed Adult AML|Refractory AML | 2024-08-31 | PHASE1 |
| NCT00003215 | Swiss Cancer Institute | Lymphoma | 1997-04 | PHASE3 |
| NCT00006122 | European Organisation for Research and Treatment of Cancer - EORTC | Leukemia | 2000-06 | PHASE2 |
| NCT04331743 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Hepatocellular Carcinoma | 2021-06-05 | PHASE1 |
| NCT02728050 | University of Washington|National Cancer Institute (NCI)|Bayer | Acute Biphenotypic Leukemia|Acute Myeloid Leukemia|de Novo Myelodysplastic Syndrome|Myelodysplastic Syndrome|Myeloproliferative Neoplasm | 2016-12-01 | PHASE1|PHASE2 |
| NCT02339740 | Children´s Oncology Group|National Cancer Institute (NCI) | Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA | 2015-07-21 | PHASE3 |
| NCT00169208 | Lymphoma Study Association | Follicular Lymphoma | 2001-04 | PHASE2 |
| NCT01801046 | University of Southern California|National Cancer Institute (NCI) | Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Childhood Acute Erythroleukemia (M6)|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloblastic Leukemia With Maturation (M2)|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)|Childhood Acute Myeloid Leukemia in Remission|Childhood Acute Myelomonocytic Leukemia (M4)|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies | 2013-03-06 | PHASE1 |
| NCT00866918 | Children´s Oncology Group|National Cancer Institute (NCI) | Childhood Acute Promyelocytic Leukemia With PML-RARA|Myeloid Neoplasm | 2009-03-09 | PHASE3 |
| NCT00842595 | French Innovative Leukemia Organisation | Diffuse Large B-Cell Lymphoma | 2003-12 | PHASE2 |
| NCT02597153 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Relapsed Cutaneous T Cell Lymphom | 2015-10 | PHASE2 |
| NCT00436839 | Sanofi | Prostatic Neoplasms | 2007-01 | PHASE3 |
| NCT05330377 | Ayman H Qasrawi|Astellas Pharma Inc | Acute Myeloid Leukemia | 2023-03 | PHASE1 |
| NCT00940524 | Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb | Leukemia|Acute Lymphoblastic Leukemia | 2009-07 | PHASE1 |
| NCT06921044 | Xiaohui He|CSPC Ouyi Pharmaceutical Co., Ltd. | Diffuse Large B-Cell Lymphoma | 2025-04-16 | PHASE2 |
| NCT00417079 | Sanofi | Neoplasms|Prostatic Neoplasms | 2007-01 | PHASE3 |
| NCT00119730 | Dana-Farber Cancer Institute|Massachusetts General Hospital|Biogen | Mantle Cell Lymphoma | 2005-02 | PHASE2 |
| NCT03182244 | Astellas Pharma Inc | AML With FLT3 Mutation | 2017-10-25 | PHASE3 |
| NCT00003068 | University of Arizona | Breast Cancer|Drug+Agent Toxicity by Tissue+Organ | 1997-06 | PHASE2 |
| NCT03531918 | Fred Hutchinson Cancer Center|Pfizer | Acute Myeloid Leukemia | 2018-09-14 | PHASE1|PHASE2 |
| NCT02921061 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) | Mixed Phenotype Acute Leukemia|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Recurrent High Risk Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory High Risk Myelodysplastic Syndrome|Untreated Adult Acute Myeloid Leukemia | 2016-11-17 | PHASE1|PHASE2 |
| NCT00186875 | St. Jude Children´s Research Hospital | Acute Lymphoblastic Leukemia|Lymphoma, Lymphoblastic | 2003-11 | PHASE2 |
| NCT04548700 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Treatment-na?ve|Peripheral T Cell Lymphoma | 2020-12-24 | PHASE1 |
| NCT00002531 | Johann Wolfgang Goethe University Hospital | Leukemia | 1993-01 | PHASE2 |
| NCT02419755 | St. Jude Children´s Research Hospital | Mixed Lineage Acute Leukemia|Acute Myeloid Leukemia|Acute Lymphoid Leukemia | 2015-04-14 | PHASE2 |
| NCT06594640 | Institute of Hematology & Blood Diseases Hospital, China | Diffuse Large B-cell Lymphoma | 2024-05-30 | PHASE1|PHASE2 |
| NCT00372593 | Children´s Oncology Group|National Cancer Institute (NCI) | Leukemia | 2006-08 | PHASE3 |
| NCT05345938 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Relapsed or Refractory Acute Myeloid Leukemia (AML) | 2022-06-14 | PHASE1|PHASE2 |
| NCT02597387 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Relapsed DLBCL and PT+NKCLs | 2015-08 | PHASE2 |
| NCT01839240 | University of Chicago|National Cancer Institute (NCI) | Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia | 2012-06-06 | PHASE1 |
| NCT03150004 | Medical College of Wisconsin | Acute Myeloid Leukemia|Myelodysplastic Syndrome | 2017-06-14 | PHASE2 |
| NCT00182741 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) | Prostate Cancer | 2004-09 | PHASE2 |
| NCT05603884 | The First Affiliated Hospital of Xiamen University|Chipscreen Biosciences, Ltd.|CSPC Pharmaceutical Group Limited|Fujian Provincial Hospital|Fujian Cancer Hospital|Zhangzhou manicipal hospital of Fujian Province|Jieyang People´s Hospital|Huizhou Municipal Central Hospital | Leukemia, Myeloid, Acute|AML Stage, Adult | 2022-12-01 | PHASE2 |
| NCT00180128 | Technische Universit?t Dresden | Leukemia, Promyelocytic, Acute | 2000-01 | PHASE4 |
| NCT00005867 | Lymphoma Trials Office | Lymphoma | 1998-01 | PHASE3 |
| NCT05774028 | The First Affiliated Hospital with Nanjing Medical University | NK-T-Cell Lymphoma, Extranodal | 2023-04 | PHASE2 |
| NCT05496894 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Relapsing Multiple Sclerosis | 2022-08 | PHASE2 |
| NCT00337246 | Cancer Research UK | Leukemia | 2005-07 | PHASE2 |
| NCT02848183 | Samsung Medical Center | Pediatric Acute Myeloid Leukemia | 2016-01 | PHASE2 |
| NCT00556127 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | Diffuse Large B-Cell Lymphoma|POOR PROGNOSIS | 2002-06 | PHASE2 |
| NCT00146159 | Wyeth is now a wholly owned subsidiary of Pfizer | Secondary Progressive Multiple Sclerosis | 2005-03 | PHASE3 |
| NCT05575973 | Jianfeng Zhou|CSPC Ouyi Pharmaceutical Co., Ltd. | Diffuse Large B-cell Lymphoma | 2022-10-10 | PHASE2 |
| NCT00840684 | Institut Paoli-Calmettes | Leukemia | 2009-01 | PHASE1|PHASE2 |
| NCT00136084 | St. Jude Children´s Research Hospital|National Cancer Institute (NCI) | Leukemia, Myelocytic, Acute | 2002-08 | PHASE3 |
| NCT00882076 | Milton S. Hershey Medical Center | Leukemia | 2009-03 | PHASE1 |
| NCT02856685 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Non-Hodgkin´s Lymphoma | 2016-08 | PHASE1|PHASE2 |
| NCT00447473 | The Methodist Hospital Research Institute|Bayer | Prostatic Neoplasms | 2006-07 | PHASE2 |
| NCT00780104 | Abramson Cancer Center at Penn Medicine | Myeloid Leukemias|AML|Leukemia|CML | 2007-07 | PHASE1 |
| NCT01204710 | Eli Lilly and Company | Prostate Cancer | 2010-10 | PHASE2 |
| NCT01842672 | New York Medical College | Acute Lymphoblastic Leukemia|Acute Myelogenous Leukemia|Lymphoblastic Lymphoma|Diffuse Large B-cell Lymphoma|Burkitt Lymphoma+Leukemia | 2013-03 | PHASE1|PHASE2 |
| NCT02462265 | Oshadi Drug Administration | Acute Myeloid Leukemia|Lymphoid Leukemia | 2017-01 | PHASE2 |
| NCT05344742 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumor | 2022-04 | PHASE1 |
| NCT07058103 | The Affiliated Hospital of Xuzhou Medical University | Angioimmunoblastic T-Cell Lymphoma Recurrent|Angioimmunoblastic T-Cell Lymphoma Refractory | 2025-04-01 | PHASE2 |
| NCT03983824 | National Cancer Institute (NCI) | Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia | 2020-05-05 | PHASE1 |
| NCT02523976 | Institute of Hematology & Blood Diseases Hospital, China | Acute,Leukemia, Lymphoid | 2015-08-01 | PHASE2 |
| NCT05495100 | Second Affiliated Hospital, School of Medicine, Zhejiang University|Ningbo No. 1 Hospital|Jinhua Central Hospital|Huizhou Municipal Central Hospital | Peripheral T Cell Lymphoma | 2022-08-11 | PHASE2 |
| NCT00002544 | Arbeitsgemeinschaft fur Internistische Onkologie | Breast Cancer | 1993-05 | PHASE3 |
| NCT05052970 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Relapsed or Refractory Multiple Myeloma | 2021-10-20 | PHASE1 |
| NCT02306291 | GlycoMimetics Incorporated | Leukemia, Myeloid, Acute | 2015-03 | PHASE1|PHASE2 |
| NCT06262438 | Princess Maxima Center for Pediatric Oncology|Daiichi Sankyo | Acute Myeloid Leukemia in Children | 2024-02-06 | PHASE2 |
| NCT00853008 | PETHEMA Foundation | Acute Lymphoblastic Leukemia | 2003-01 | PHASE4 |
| NCT04921878 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumors | 2021-07-30 | PHASE1 |
| NCT02400281 | Arog Pharmaceuticals, Inc. | Acute Myeloid Leukemia | 2015-09 | PHASE1|PHASE2 |
| NCT02686593 | The University of Hong Kong | Acute Myeloid Leukemia | 2016-02-01 | PHASE2 |
| NCT01342887 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) | Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia | 2011-04 | PHASE1|PHASE2 |
| NCT00124566 | Eisai Inc. | Prostate Cancer | 2004-06 | PHASE2 |
| NCT00010075 | GERCOR - Multidisciplinary Oncology Cooperative Group | Breast Cancer | 2000-01 | PHASE2 |
| NCT05089461 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Malignant Tumor | 2022-03-07 | PHASE2 |
| NCT02198482 | University of Ulm | Acute Myeloid Leukemia (AML)|High-risk Myelodysplastic Syndrome (MDS) | 2016-02 | PHASE2 |
| NCT02299518 | Alice Mims|Karyopharm Therapeutics Inc | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia | 2015-05-18 | PHASE1 |
| NCT02484391 | Wake Forest University Health Sciences|National Cancer Institute (NCI) | Granulocytic Sarcoma|Recurrent Adult Acute Myeloid Leukemia | 2015-09 | PHASE1 |
| NCT05875428 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Diffuse Large B-Cell Lymphoma | 2023-07-10 | PHASE2 |
| NCT00006045 | Facet Biotech|National Cancer Institute (NCI) | Leukemia | 2000-03 | PHASE3 |
| NCT01154439 | Gruppo Italiano Malattie EMatologiche dell´Adulto | Leukemia | 2010-10 | PHASE1 |
| NCT07490288 | Institute of Hematology & Blood Diseases Hospital, China | AML | 2026-04-30 | NA |
| NCT05173545 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recurrent+Refractory Lymphoma | 2019-07-29 | PHASE1 |
| NCT07354698 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Papillary Thyroid Cancer | 2026-02-01 | PHASE4 |
| NCT00004071 | Pfizer | Prostate Cancer | 1999-08 | PHASE2|PHASE3 |
| NCT04196010 | University of Washington | Myeloid Neoplasm|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia | 2020-05-08 | PHASE1 |
| NCT01144403 | Hoffmann-La Roche | Diffuse Large B-Cell Lymphoma | 2010-06 | PHASE2 |
| NCT02688140 | Technische Universit?t Dresden|Gruppo Italiano Malattie EMatologiche dell´Adulto|Groupe Francophone des Myelodysplasies|HOVON - Dutch Haemato-Oncology Association|Programa para el Tratamiento de Hemopatías Malignas|German Federal Ministry of Education and Research|Teva Pharmaceuticals Europe | Acute Promyelocytic Leukemia | 2016-06 | PHASE3 |
| NCT05458180 | Tianjin Medical University Cancer Institute and Hospital|CSPC Ouyi Pharmaceutical Co., Ltd. | Peripheral T-cell Lymphoma | 2022-07-07 | PHASE1 |
| NCT05441761 | Peking Union Medical College Hospital|CSPC Ouyi Pharmaceutical Co., Ltd. | Treatment|Peripheral T-cell Lymphoma | 2022-05-01 | PHASE1|PHASE2 |
| NCT04293562 | Children´s Oncology Group|National Cancer Institute (NCI) | Acute Myeloid Leukemia | 2020-07-21 | PHASE3 |
| NCT07486479 | The First Affiliated Hospital of Soochow University|CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Acute Myeloid Leukemia (AML) | 2026-03-10 | PHASE3 |
| NCT00002835 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Lymphoma | 1995-10-30 | PHASE3 |
| NCT02021825 | Xuanwu Hospital, Beijing | Neuromyelitis Optica|Neuromyelitis Optica Spectrum Disorders | 2009-03 | PHASE4 |
| NCT05299164 | Institute of Hematology & Blood Diseases Hospital, China|CSPC Ouyi Pharmaceutical Co., Ltd. | Non Hodgkin Lymphoma | 2022-05-15 | PHASE1 |
| NCT00005998 | Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI) | Lymphoma | 2000-01 | PHASE2 |
| NCT00002565 | M.D. Anderson Cancer Center|National Cancer Institute (NCI) | Lymphoma | 1994-05-25 | PHASE3 |
| NCT06758726 | Institute of Hematology & Blood Diseases Hospital, China | AML | 2024-12-31 | NA |
| NCT01371981 | National Cancer Institute (NCI) | Acute Myeloid Leukemia|Leukemia Cutis|Myeloid Neoplasm|Myeloid Sarcoma | 2011-06-20 | PHASE3 |
| NCT05551598 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Neuromyelitis Optica Spectrum Disorder | 2022-11-28 | PHASE2 |
| NCT04927481 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Breast Cancer | 2021-06-11 | PHASE2 |
| NCT06761417 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Solid Tumors|Children|Adolescents | 2025-01-24 | PHASE2 |
| NCT00254410 | M.D. Anderson Cancer Center|OSI Pharmaceuticals|Genentech, Inc. | Chronic Lymphocytic Leukemia | 2005-03-14 | PHASE2 |
| NCT03926624 | Delta-Fly Pharma, Inc. | Leukemia, Myeloid, Acute | 2019-11-22 | PHASE3 |
| NCT02070458 | Case Comprehensive Cancer Center|National Cancer Institute (NCI) | Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia | 2014-10-08 | PHASE1 |
| NCT02044796 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) | Acute Biphenotypic Leukemia|de Novo Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia | 2014-01-23 | PHASE1|PHASE2 |
| NCT00004197 | University of Nebraska|National Cancer Institute (NCI) | Lymphoma | 1999-06-25 | PHASE2 |
| NCT00002498 | Leiden University Medical Center | Breast Cancer | 1992-07 | PHASE2 |
| NCT00032149 | Lymphoma Trials Office | Lymphoma | 2001-10 | PHASE1|PHASE2 |
| NCT05717764 | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Recurrent Metastatic Nasopharyngeal Carcinoma | 2023-02 | PHASE3 |
| NCT00452387 | Accelerated Community Oncology Research Network|Bayer | Metastatic Prostate Cancer | 2007-05 | PHASE2 |
| NCT00005985 | Masonic Cancer Center, University of Minnesota | Lymphoma | 2000-08 | PHASE2 |
| NCT02521493 | Children´s Oncology Group|National Cancer Institute (NCI) | Acute Myeloid Leukemia|Down Syndrome|Myelodysplastic Syndrome|Myeloid Leukemia Associated With Down Syndrome|Myeloproliferative Neoplasm | 2015-12-23 | PHASE3 |
| NCT00151255 | University of Ulm | Acute Myeloid Leukemia | 2004-06 | PHASE3 |
| NCT03026842 | The First Hospital of Jilin University|The Second Affiliated Hospital of Dalian Medical University|Second Hospital of Jilin University|Jilin University | Acute Myeloid Leukemia | 2017-01 | PHASE4 |
| NCT03258320 | Shanghai Jiao Tong University School of Medicine|Fudan University|Qilu Hospital of Shandong University | Prostate Cancer Patients | 2015-01 | PHASE2|PHASE3 |
| NCT03591510 | Novartis Pharmaceuticals | FLT3-mutated Acute Myeloid Leukemia | 2019-03-13 | PHASE2 |
| NCT04902027 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recurrent Head and Neck Cancer|Metastatic Head and Neck Cancer | 2021-07-01 | PHASE1 |
| NCT05620862 | Sun Yat-sen University|CSPC Ouyi Pharmaceutical Co., Ltd. | Pediatric Solid Tumor | 2022-10-25 | PHASE1 |
| NCT03012672 | University of Washington|National Cancer Institute (NCI) | Acute Leukemia of Ambiguous Lineage|Acute Myeloid Leukemia|Myeloid Neoplasm | 2016-12-30 | PHASE2 |
| NCT07168317 | The Affiliated Hospital of Xuzhou Medical University | New Diagnosed Angioimmunoblastic T-Cell Lymphoma | 2025-08-01 | PHASE2 |
| NCT02632708 | Institut de Recherches Internationales Servier|Celgene Corporation | Newly Diagnosed Acute Myeloid Leukemia (AML)|Untreated AML|AML Arising From Myelodysplastic Syndrome (MDS)|AML Arising From Antecedent Hematologic Disorder (AHD)|AML Arising After Exposure to Genotoxic Injury | 2015-12-31 | PHASE1 |
| NCT03839446 | Robert Redner, MD|Pfizer | Acute Myeloid Leukemia | 2019-02-28 | PHASE2 |
| NCT04797767 | University of Washington|AbbVie | Acute Biphenotypic Leukemia|Acute Myeloid Leukemia|Mixed Phenotype Acute Leukemia|Myeloid Neoplasm|Relapsed Acute Biphenotypic Leukemia|Relapsed Acute Myeloid Leukemia|Relapsed Mixed Phenotype Acute Leukemia|Relapsed Myeloid Neoplasm|Refractory Acute Biphenotypic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Mixed Phenotype Acute Leukemia|Refractory Myeloid Neoplasm|Recurrent Myeloid Sarcoma | 2022-02-04 | PHASE1|PHASE2 |
| NCT00003407 | Rush University Medical Center|National Cancer Institute (NCI) | Drug+Agent Toxicity by Tissue+Organ|Leukemia|Myelodysplastic Syndromes|Neutropenia | 2001-02-13 | PHASE2 |
| NCT00109837 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Leukemia | 2005-04 | PHASE2 |
| NCT04375631 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) | Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent Myelodysplastic Syndrome|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelomonocytic Leukemia|Refractory Mixed Phenotype Acute Leukemia|Refractory Myelodysplastic Syndrome|Refractory Acute Leukemia of Ambiguous Lineage|Refractory Acute Undifferentiated Leukemia | 2020-12-03 | PHASE1 |
| NCT02756572 | University of Washington|National Cancer Institute (NCI) | Blasts 10 Percent or More of Bone Marrow Nucleated Cells|Chronic Myelomonocytic Leukemia-2|High Grade Malignant Neoplasm|Myelodysplastic Syndrome|Myelodysplastic Syndrome With Excess Blasts-2|Myeloid Neoplasm|Previously Treated Myelodysplastic Syndrome|Recurrent Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia | 2016-09-22 | PHASE2 |
| NCT01768897 | Wake Forest University Health Sciences|National Cancer Institute (NCI) | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Recurrent Adult Acute Myeloid Leukemia | 2013-01 | PHASE1 |
| NCT00003957 | Fox Chase Cancer Center|National Cancer Institute (NCI) | Lymphoma | 1998-12 | PHASE2 |
| NCT05823701 | The First Affiliated Hospital of Soochow University | Diffuse Large B-Cell Lymphoma | 2022-09-30 | PHASE2 |
| NCT00052299 | European Organisation for Research and Treatment of Cancer - EORTC|Gruppo Italiano Malattie EMatologiche dell´Adulto | Leukemia | 2002-09 | PHASE3 |
| NCT01184898 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University|University of Pennsylvania | AML | 2010-07 | NA |
| NCT02573363 | University of Chicago|National Cancer Institute (NCI) | Acute Myeloid Leukemia | 2015-10-07 | PHASE1 |
| NCT00003343 | Pfizer | Prostate Cancer | 1998-03 | PHASE3 |
| NCT01186640 | German CLL Study Group|Genzyme, a Sanofi Company|University of Cologne | T-cell-prolymphocytic Leukemia | 2010-06 | PHASE2 |
| NCT01133158 | Grupo Espa?ol de Linfomas y Transplante Autólogo de Médula ósea | Non-Hodgkin´s Lymphoma | 2009-07 | PHASE2 |
| NCT00002658 | Medical Research Council | Leukemia|Neutropenia | 1994-01 | PHASE3 |
| NCT07372352 | The First Affiliated Hospital of Soochow University | Peripheral T Cells Lymphoma (PTCL) | 2026-01-15 | PHASE2 |
| NCT06514313 | Yizhuo Zhang | Soft Tissue Sarcoma | 2024-07-03 | PHASE2 |
| NCT01004497 | The Catholic University of Korea | Acute Lymphoblastic Leukemia | 2010-03 | PHASE2 |
| NCT03776279 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Relapsed or Refractory Peripheral T-cell and NK+T-cell Lymphoma | 2018-04-02 | PHASE2 |
| NCT00795002 | National Cancer Institute (NCI) | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia | 2008-11 | PHASE2 |
| NCT00004124 | SWOG Cancer Research Network|National Cancer Institute (NCI)|Cancer and Leukemia Group B | Prostate Cancer | 1999-10-15 | PHASE3 |
| NCT00274963 | German CLL Study Group | Chronic Lymphocytic Leukemia | 2004-10 | PHASE2 |
| NCT00512252 | Washington University School of Medicine | Leukemia, Myeloid, Acute | 2007-07 | PHASE1|PHASE2 |
| NCT00546377 | Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI) | Leukemia|Lymphoma | 2005-07 | PHASE1|PHASE2 |
| NCT00002549 | European Organisation for Research and Treatment of Cancer - EORTC | Leukemia | 1993-11 | PHASE3 |
| NCT06489808 | Institute of Hematology & Blood Diseases Hospital, China | Relapsed+Refractory Large B-Cell Lymphoma | 2024-05-28 | PHASE2 |
| NCT01403415 | National Cancer Institute (NCI) | Childhood B Acute Lymphoblastic Leukemia|Childhood T Acute Lymphoblastic Leukemia|Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Lymphoblastic Lymphoma | 2011-09 | PHASE1 |
| NCT00458848 | Gruppo Italiano Malattie EMatologiche dell´Adulto | Leukemia | 2004-10 | PHASE2 |
| NCT05739630 | The First Affiliated Hospital of Soochow University | Acute Leukemia | 2023-01-01 | PHASE2|PHASE3 |
| NCT05955261 | St. Jude Children´s Research Hospital|AbbVie | Acute Myeloid Leukemia | 2023-07-25 | PHASE2 |
| NCT00499018 | Fondazione Italiana Linfomi - ETS|Centro di Riferimento per l´Epidemiologia e la Prev. Oncologica Piemonte | Diffuse Large B-Cell Lymphoma|IPI?2 | 2006-01 | PHASE3 |
| NCT04900766 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unresectable or Metastatic Bone and Soft Tissue Sarcoma | 2021-08-11 | PHASE1 |
| NCT01349972 | National Cancer Institute (NCI) | Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia | 2011-04 | PHASE2 |
| NCT01729845 | Fred Hutchinson Cancer Center|National Cancer Institute (NCI) | Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia | 2012-12-20 | PHASE1|PHASE2 |
| NCT00193479 | SCRI Development Innovations, LLC|Genentech, Inc.|Amgen | Non-Hodgkins Lymphoma | 2003-04 | PHASE2 |
| NCT02687386 | Dr David Ziegler|Engeneic Pty Limited | Solid Tumours|CNS Tumours | 2016-02-08 | PHASE1 |
| NCT05313958 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Third Affiliated Hospital, Sun Yat-Sen University|Maternal and Child Health Hospital of Foshan|The First Affiliated Hospital of Guangzhou Medical University|Second Xiangya Hospital of Central South University|Jiangxi Province Children´s Hospital|Southern Medical University, China|The First Affiliated Hospital of Nanchang University|Guangzhou First People´s Hospital|First Affiliated Hospital of Shantou University Medical College | Leukemia, Monocytic, Acute|Pediatric AML | 2021-12-01 | PHASE2|PHASE3 |
| NCT01127009 | Case Comprehensive Cancer Center | Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Recurrent Adult Acute Myeloid Leukemia | 2010-07 | PHASE1 |
| NCT03735446 | Dana-Farber Cancer Institute|Eli Lilly and Company | Acute Myeloid Leukemia|Myelodysplastic Syndromes | 2019-01-18 | PHASE1 |
| NCT00408278 | PETHEMA Foundation | Acute Promyelocytic Leukemia | 2005-07 | PHASE4 |
| NCT01564784 | Pfizer|UCB Pharma | Acute Lymphoblastic Leukemia | 2012-08-02 | PHASE3 |
| NCT00304291 | State University of New York at Buffalo|EMD Serono | Neuromyelitis Optica|Myelitis, Transverse|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System | 2001-08 | PHASE4 |
| NCT00002517 | European Organisation for Research and Treatment of Cancer - EORTC | Leukemia|Myelodysplastic Syndromes | 1993-03 | PHASE3 |
| NCT00003232 | NCIC Clinical Trials Group | Pain|Prostate Cancer|Quality of Life | 1997-11-24 | PHASE3 |
| NCT00002598 | Memorial Sloan Kettering Cancer Center | Leukemia | 1994-06 | PHASE2 |
| NCT01830777 | Massachusetts General Hospital | Acute Myelogenous Leukemia | 2013-05 | PHASE1 |
| NCT06621212 | First Affiliated Hospital of Zhejiang University|CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Relapsed+Refractory Acute Myeloid Leukaemia|Myeloid Malignancy | 2024-07-05 | PHASE2 |
| NCT00901927 | M.D. Anderson Cancer Center|Cephalon | Follicular Lymphoma | 2009-05 | PHASE2 |
| NCT00906945 | Washington University School of Medicine | Leukemia, Myeloid, Acute | 2011-02 | PHASE1|PHASE2 |
| NCT00017563 | OHSU Knight Cancer Institute|National Cancer Institute (NCI) | Prostate Cancer | 2000-09 | PHASE2 |
| NCT02303821 | Amgen|Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator|Innovative Therapies For Children with Cancer Consortium | Acute Lymphoblastic Leukemia (ALL) | 2015-02-16 | PHASE1 |
| NCT02626338 | Arog Pharmaceuticals, Inc. | Relapsed+Refractory Acute Myeloid Leukemia (AML) | 2016-02 | PHASE1|PHASE2 |
| NCT05848687 | Tanja Andrea Gruber|The Pediatric Oncology Experimental Therapeutics Investigators´ Consortium|Amgen|Lucile Packard Foundation for Children´s Health|Kura Oncology, Inc.|United States Department of Defense|Cannonball Kid´s Cancer | Lymphoblastic Leukemia | 2023-11-03 | PHASE1|PHASE2 |
| NCT00003728 | European Organisation for Research and Treatment of Cancer - EORTC | Leukemia|Lymphoma | 1998-12 | PHASE3 |
| NCT03860844 | Sanofi | Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia | 2019-08-06 | PHASE2 |
| NCT00002701 | European Organisation for Research and Treatment of Cancer - EORTC|Gruppo Italiano Malattie EMatologiche dell´Adulto | Leukemia | 1995-10 | PHASE3 |
| NCT05990985 | The First Hospital of Jilin University|CSPC Ouyi Pharmaceutical Co., Ltd. | Diffuse Large B-cell Lymphoma | 2023-09-01 | NA |
| NCT00712582 | Memorial Sloan Kettering Cancer Center|Genentech, Inc.|Columbia University | Non-Hodgkin´s Lymphoma | 2008-07-01 | PHASE2 |
| NCT00002259 | Lederle Laboratories | Sarcoma, Kaposi|HIV Infections | | PHASE2 |
| NCT00003297 | Georgetown University|National Cancer Institute (NCI) | Ovarian Cancer | 1997-12 | PHASE1|PHASE2 |
| NCT03563560 | Sumitomo Pharma Co., Ltd. | Acute Myeloid Leukemia | 2018-05-15 | PHASE1 |
| NCT01027923 | Washington University School of Medicine | Leukemia, Myeloid, Acute | 2010-05 | PHASE1 |
| NCT05958719 | Institute of Hematology & Blood Diseases Hospital, China | Peripheral T Cell Lymphoma|Epigenetic Repression | 2023-03-02 | PHASE2 |
| NCT00143975 | University of Ulm | Leukemia, Myeloid, Acute | 2004-06 | PHASE2 |
| NCT05941585 | Institute of Hematology & Blood Diseases Hospital, China | Acute Myeloid Leukemia | 2023-08-08 | NA |
| NCT04024241 | Shenzhen People´s Hospital | Acute Myelogenous Leukemia|Chemotherapy | 2017-09-01 | |
| NCT04719065 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumor | 2021-01-13 | PHASE1 |
| NCT00002719 | European Organisation for Research and Treatment of Cancer - EORTC|Gruppo Italiano Malattie EMatologiche dell´Adulto | Leukemia|Neutropenia | 1995-12 | PHASE3 |
| NCT00661492 | US Oncology Research|Eli Lilly and Company|Oregon Health and Science University | Androgen-independent Prostate Cancer | 2008-05 | PHASE2 |
| NCT00290511 | M.D. Anderson Cancer Center|Genentech, Inc.|Biogen | Lymphoma | 2004-06-29 | PHASE2 |
| NCT00510887 | Duke University|Millennium Pharmaceuticals, Inc. | Lymphoma, Follicular | 2007-01 | PHASE2 |
| NCT00331344 | National Cancer Institute (NCI) | Adenocarcinoma of the Prostate|Recurrent Prostate Cancer|Stage IV Prostate Cancer | 2006-04 | PHASE1|PHASE2 |
| NCT00317408 | European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma | Lymphoma | 2004-04 | NA |
| NCT01522443 | Exelixis | Prostate Cancer|Castration Resistant Prostate Cancer|Pain|Prostatic Neoplasms | 2012-03 | PHASE3 |
| NCT01382147 | Prof. Dr. Wolfgang Hiddemann|Kompetenznetz Leuk?mien | Acute Myeloid Leukemia | 2009-07-01 | PHASE3 |
| NCT00002700 | European Organisation for Research and Treatment of Cancer - EORTC|Acute Leukemia French Association | Leukemia|Lymphoma | 1995-08 | PHASE3 |
| NCT06220097 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology|CSPC Pharmaceutical Group Limited | B-cell Acute Lymphoblastic Leukemia|B-cell Lymphoma Refractory | 2022-02-01 | PHASE2 |
| NCT00006250 | Lymphoma Trials Office | Lymphoma | 2000-05 | PHASE3 |
| NCT00550992 | Dutch Childhood Oncology Group|BFM Germany|CORS Monza Italy|Associazione Italiana Ematologia Oncologia Pediatrica|Australian and New Zealand Children´s Oncology Group|BFM Austria|CLCG France Belgium Portugal|COALL Germany|CPH, Czech republic|DFCI consortium USA|FRALLE France|Hong Kong Government|MD Anderson USA|NOPHO Scandinavian countries|PINDA, Chile|PPLLSG Poland|Seattle USA|SJCRH USA|UKCCSG United Kingdom | Leukemia | 2006-01 | NA |
| NCT00079105 | Newcastle-upon-Tyne Hospitals NHS Trust | Lymphoma | 2004-01 | PHASE2 |
| NCT00053131 | Roswell Park Cancer Institute | Leukemia | 1999-01 | PHASE2 |
| NCT00003003 | Dartmouth-Hitchcock Medical Center|National Cancer Institute (NCI) | Leukemia | 1996-09 | PHASE1 |
| NCT04195945 | Fred Hutchinson Cancer Center|Jazz Pharmaceuticals | Acute Myeloid Leukemia|Myeloid Neoplasm | 2020-03-11 | PHASE2 |
| NCT00274807 | The Cleveland Clinic|National Cancer Institute (NCI) | Leukemia | 2001-06 | PHASE2 |
| NCT00059631 | M.D. Anderson Cancer Center|Millennium Pharmaceuticals, Inc.|National Cancer Institute (NCI) | Prostate Cancer | 2003-03-20 | PHASE1 |
| NCT00656084 | US Oncology Research|Eli Lilly and Company | Relapsed or Refractory Mantle Cell Lymphoma (MCL) | 2004-12 | PHASE2 |
| NCT00002688 | University Medical Center Groningen | Leukemia | 1995-02 | PHASE2 |
| NCT01065727 | Rennes University Hospital | Multiple Sclerosis | 2010-02 | NA |
| NCT00002912 | National Cancer Institute (NCI) | Leukemia | 1997-01 | PHASE1 |
| NCT02535806 | Children´s Mercy Hospital Kansas City|Millennium Pharmaceuticals, Inc. | Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma | 2015-07 | PHASE2 |
| NCT00100477 | US Department of Veterans Affairs|Immunex Corporation|SmithKline Beecham|Amgen | Non-Hodgkin´s Lymphoma|Leukemia | 1998-08 | PHASE2 |
| NCT00079482 | Cephalon | Acute Myeloid Leukemia | 2003-10 | PHASE2 |